Who owns Personalis, Inc. (PSNL)? Elite investor 13F holders

1 tracked elite investors reported holding Personalis, Inc as of 2026-06-30, including Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

1 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Ancora Advisors / Ancora HoldingsPERSONALIS INCSHARE2026-06-302026-08-14 00:00:009246.00 USD690.000000SharesholdOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown